Source: http://www.reuters.com/finance/stocks/financialHighlights?symbol=CTIC.W

Investment Highlights

No less than seven class action lawsuits have been filed by various law firms against CTIC and certain officers for violations of federal securities laws in connection to their public statements affecting stock purchased between May 5, 2009, and February 8, 2010.

CTIC last week announced that the U.S. Food and Drug Administration (”FDA”) has completed its inspection of the facility at NerPharMa (a pharmaceutical manufacturing company belonging to Nerviano Medical Sciences Srl, in Nerviano, Italy), which manufactures CTIC’s drug pixantrone and has found the site in compliance and acceptable for continued manufacturing of the drug product. CTIC has a New Drug Application (”NDA”) under review at the FDA for pixantrone to treat relapsed/refractory aggressive non-Hodgkin’s lymphoma. As previously announced, the FDA’s Oncologic Drugs Advisory Committee (”ODAC”) will review the NDA for pixantrone on March 22, 2010, and the FDA is expected to make a final decision on approval by April 23, 2010. Nerviano Medical Sciences is the largest pharmaceutical R&D facility in Italy and one of the largest oncology-focused, integrated discovery and development companies in Europe.

CTIC announced in early March that it received a statement from the Gynecologic Oncology Group (GOG) leadership that the phase III GOG-212 clinical trial of CTIC’s OPAXIO(TM) used as maintenance therapy for ovarian cancer remains a high priority and enrollment will continue. The GOG clarified that the recent results of the GOG-218 clinical trial bevacizumab in maintenance therapy for ovarian cancer has not influenced the importance of completing the GOG-212 clinical trial. GOG is one of the National Cancer Institute’s funded cooperative cancer research groups. The GOG is a multidisciplinary cooperative clinical trial research group focused on the study of gynecologic malignancies. The GOG is conducting phase III trials in ovarian cancer and other gynecologic cancers and has established standard treatments for these diseases in the United States.

CITC’s 2009 Key Accomplishments and Targeted 2010 Milestones

  • Pixantrone New Drug Application (”NDA”) for relapsed/refractory aggressive non-Hodgkin’s lymphoma filed with the U.S. Food and Drug Administration (the “FDA”) and accepted for review in 2009. The FDA established Prescription Drug User Fee Act (PDUFA) date of April 23, 2010.
  • Initiated a Marketing Authorization Application (”MAA”) for pixantrone in Europe in 2009 and received Orphan Drug Designation by the European Medicines Agency. CTIC expects to file a Marketing Authorization Application in mid-2010.
  • Phase II clinical data on OPAXIO demonstrated high rates of pathologic complete remissions for treatment of patients with advanced esophageal cancer paving way for potential registration trial as radiation sensitizer. CTIC expects to meet with the FDA in the first half of 2010 to discuss a potential registration trial for OPAXIO as a radiation sensitizer.
  • Decreased debt in 2009 by $57.4 million through exchanges and eliminated all of outstanding preferred stock.
  • Added in 2009 to the Russell 2000, 3000 and Global Indices as well as the Nasdaq Global Biotechnology Index.
  • Adopted Shareholder Rights Plan designed to deter coercive takeover tactics, and to prevent an acquirer from gaining control of CTIC without offering a fair price to all of CTIC’s shareholders.
  • Received net proceeds of $136 million in 2009 through sale of Zevalin and investments by institutions to fund operations and decrease debt.

Source: http://www.celltherapeutics.com/

Technical Analysis

Source: http://stockcharts.com

CTIC is trading above its 13-day moving average. This is considered to be the sign of a bullish trend. There is added weight to this indication because the moving average is rising and suggests that there has been buying interest in this stock.

CTIC’s recent volatility has been greater than normal. This is evidenced by the increased distance between the upper and lower Bollinger Bands. These bands measure volatility using standard deviation and a large width is due to high volatility. Additionally, CTIC is trading within its Bollinger Bands. This is a normal condition and suggests that the stock is neither overbought nor oversold relative to the recent price action.

The MACD for CTIC currently indicates a strong bullish signal for two reasons. First, the MACD is above the signal line, a 9-day moving average. Second, the MACD is above 0, which implies that the underlying moving averages are trending higher.

Comparative Analysis

Advanced Cardiac Therapeutics (Laguna Beach, CA) a development-stage electrophysiology and radiometry medical device company focused on energy delivery via catheters for cardiac ablation, closed a $5M Series b financing. Participants include NBGI Ventures.